 55 ORR, 73 DCR, and 7.7 month PFS in DKK1-highPD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical trial CAMBRIDGE, Mass. , Nov. 7, 2022 PRNewswire -- Leap Therapeutics, Inc. Nasdaq:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish study evaluating DKN-01 in combination with tislelizumab, BeiGenes anti-PD-1 antibody, in second-line gastroesophageal adenocarcinoma GEA cancer patients whose tumors express high levels of DKK1 DKK1-high at the Society of Immunotherapy for Cancer SITC 37th Annual Meeting being held in Boston, MA on November 8-12, 2022. 